Clinical practice guidelines for the management of biliary tract cancers 2015: the 2<sup>nd</sup> English edition
Masaru Miyazaki(NTT (Japan)), Tadahiro Takada(Teikyo University), Hiroaki Shimizu(Chiba University), Katsuhiko Uesaka(Shizuoka Cancer Center), Hideyuki Yoshitomi(Dokkyo Medical University Saitama Medical Center), Masami Tabata(Matsunami General Hospital), Hiroyuki Iasayama(The University of Tokyo), Koji Murakami(Laerdal (Norway)), Toshifumi Wakai(Niigata University Medical and Dental Hospital), Naotaka Fujita(Sendai Medical Center), Toshio Tsuyuguchi(Chiba University), Tsukasa Takayashiki(Chiba University), Itaru Endo(Yokohama City University), Masayuki Ohtsuka(Chiba University), Junji Furuse(Kanagawa Prefectural Hospital Organization), Hisafumi Kinoshita(Kurume University), Takuji Okusaka(National Cancer Centre Japan), Kenji Yamao(Aichi Cancer Center), Michiaki Unno(Tohoku University), Satoshi Hirano(Hokkaido University of Science), Kazuaki Shimada(Japan Aerospace Exploration Agency), Masato Nagino(Daido University), Masahiro Yoshida(Jikei University School of Medicine), Takehiro Ota(Ebara Hospital), Hiroshi Kijima(Hirosaki University), Kazuo Chijiiwa(University of Miyazaki), Shuichi Miyakawa(Toyota Motor Corporation (Switzerland)), Hideya Yamazaki(Kyoto Prefectural University of Medicine), Keita Wada(Teikyo University), Yasuni Nakanuma(Fukui-ken Saiseikai Hospital)
Cited by 300
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k